Why Beam Therapeutics Jumped Today

Beam Therapeutics (NASDAQ: BEAM) was up 14% midday Monday on the back of Intellia Therapeutics' (NASDAQ: NTLA) phase 1 data for its therapy to treat a genetic liver disorder.

All of the companies associated with the gene-editing technique are having a good day thanks to the data. Although the treatment for the fatal disease -- transthyretin (ATTR) amyloidosis -- is great news, the implications go far beyond any one disease.

The results are the first to show the gene-editing approach known as CRISPR-Cas9 can be both safe and effective when performed in the human body. Previous applications used cells that had been removed, edited, and reinserted into the patient.

Continue reading

Source Fool.com